```html

Uptodate: Uncontrolled Diabetes Mellitus (Type 2)

Overview

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance and relative insulin deficiency. When the disease is “uncontrolled,” blood‑glucose levels remain above target ranges despite therapy, increasing the risk of acute and long‑term complications.

Who it affects: T2DM accounts for roughly 90‑95 % of all diabetes cases in the United States. It most commonly appears after age 45 but is increasingly diagnosed in younger adults and adolescents because of rising obesity rates.

Prevalence: Worldwide, > 463 million people live with diabetes (≈ 10 % of the global adult population). In the United States, ~34.2 million adults (≈ 13 %) have diabetes, and an estimated 7.3 million have undiagnosed disease (CDC, 2023). Of those with diagnosed T2DM, about one‑third are not meeting American Diabetes Association (ADA) glycemic goals, representing the “uncontrolled” cohort.

Symptoms

Symptoms of uncontrolled T2DM can be subtle at first and may overlap with those of well‑controlled disease. Persistent hyperglycemia amplifies their frequency and severity.

Classic symptoms

• Polyuria – frequent urination due to osmotic diuresis.
• Polydipsia – excessive thirst as the body tries to compensate for fluid loss.
• Polyphagia – increased hunger despite elevated glucose levels.
• Unexplained weight loss – especially in people with severe insulin deficiency.

Other common complaints

• Fatigue or generalized weakness.
• Blurred vision caused by osmotic swelling of the lens.
• Recurrent infections (e.g., urinary tract, skin, yeast).
• Itchy skin, especially on the groin and intertriginous areas.
• Slow wound healing.
• Darkening of skin folds (acanthosis nigricans) – a sign of severe insulin resistance.

Symptoms indicating acute hyperglycemic crises

• Severe nausea, vomiting, or abdominal pain.
• Rapid breathing (Kussmaul respirations) – hallmark of diabetic ketoacidosis (DKA), though rare in T2DM.
• Fruity‑smelling breath.
• Altered mental status or coma.

Causes and Risk Factors

Uncontrolled T2DM is not a separate disease; it reflects a failure of disease‑modifying factors (genetics, lifestyle, comorbidities) and treatment adherence.

Pathophysiology

• Insulin resistance – tissues (muscle, fat, liver) respond poorly to insulin.
• Beta‑cell dysfunction – progressive loss of insulin secretory capacity.
• Excess hepatic glucose production – the liver continues to release glucose despite hyperglycemia.

Key risk factors for developing and then losing control of T2DM

• Age ≥ 45 years (risk rises with age).
• Obesity (BMI ≥ 30 kg/m²) – especially central (abdominal) adiposity.
• Family history of diabetes.
• Non‑white ethnicity (African‑American, Hispanic/Latino, Native American, South‑Asian).
• Sedentary lifestyle.
• History of gestational diabetes or polycystic ovary syndrome.
• Hypertension, dyslipidemia, or metabolic syndrome.
• Use of certain medications (e.g., glucocorticoids, antipsychotics, HIV protease inhibitors).
• Poor medication adherence, limited health literacy, or lack of access to care.

Diagnosis

Diagnosis of T2DM follows the same criteria as any diabetes, but uncontrolled disease is identified through ongoing monitoring.

Laboratory criteria (any one)

• Fasting plasma glucose (FPG) ≥ 126 mg/dL (7.0 mmol/L) after ≥ 8 h fast.
• 2‑hour plasma glucose ≥ 200 mg/dL (11.1 mmol/L) during a 75‑g oral glucose tolerance test (OGTT).
• HbA1c ≥ 6.5 % (48 mmol/mol).
• Random plasma glucose ≥ 200 mg/dL with classic hyperglycemic symptoms.

Assessing control

• HbA1c – reflects average glucose over 2‑3 months. Uncontrolled disease is usually defined as HbA1c ≥ 8 % (≥ 64 mmol/mol) or higher, depending on individualized targets.
• Fasting or pre‑prandial glucose – target < 130 mg/dL.
• Post‑prandial glucose – target < 180 mg/dL 1‑2 h after meals.
• Continuous glucose monitoring (CGM) may reveal frequent hyperglycemic excursions even when HbA1c appears acceptable.

Additional tests

• Renal function (eGFR, urine albumin‑to‑creatinine ratio) – baseline for medication selection.
• Lipid profile – cardiovascular risk assessment.
• Blood pressure measurement.
• Fundoscopic exam – for diabetic retinopathy.

Treatment Options

Management of uncontrolled T2DM requires a multifaceted approach: intensify pharmacotherapy, address lifestyle, and treat contributing conditions.

Pharmacologic therapy

1. Metformin – first‑line unless contraindicated. Reduces hepatic gluconeogenesis.
2. GLP‑1 receptor agonists (e.g., liraglutide, semaglutide) – lower glucose, promote weight loss, and have cardiovascular benefit (per ADA & NEJM 2019).
3. SGLT2 inhibitors (e.g., empagliflozin, dapagliflozin) – improve glycemic control, reduce heart failure and renal risk.
4. Insulin therapy – basal‑bolus regimens or simplified basal analogs (e.g., glargine, degludec) when oral agents are insufficient.
5. DPP‑4 inhibitors – modest glucose lowering with low hypoglycemia risk.
6. Thiazolidinediones – pioglitazone; useful in insulin‑resistant patients but limited by weight gain and edema.

Therapeutic intensification follows stepwise algorithms (ADA Standards of Care 2024). For patients with markedly high HbA1c (> 10 %), early combination therapy or starting insulin is often required.

Procedural / Device‑based options

• Continuous Glucose Monitoring (CGM) – offers real‑time glucose trends, improves adherence, and can lower HbA1c by ~0.5‑1 % (JAMA 2022).
• Insulin pump therapy – especially for patients with variable meals or hypoglycemia unawareness.
• Bariatric/metabolic surgery – for BMI ≥ 35 kg/m² with uncontrolled T2DM; remission rates up to 70 % (NIH, 2021).

Lifestyle modifications (cornerstone)

• Medical nutrition therapy – individualized, calorie‑controlled diet emphasizing whole grains, vegetables, lean protein, and limited refined carbs.
• Physical activity – ≥ 150 min/week of moderate aerobic exercise plus resistance training twice weekly.
• Weight management – 5‑10 % weight loss can improve insulin sensitivity.
• Smoking cessation – reduces cardiovascular risk.
• Alcohol moderation – ≤ 1 drink/day (women) or ≤ 2 drinks/day (men).

Living with Uptodate: Uncontrolled Diabetes Mellitus (Type 2)

Successful everyday management hinges on routine, education, and support.

Practical daily tips

• Blood glucose monitoring – test fasting and 2‑hour post‑meal values, or follow CGM alerts.
• Medication schedule – use pill organizers, set alarms, and review doses with your clinician every 3‑6 months.
• Meal planning – batch‑cook balanced meals, use the plate method (½ veggies, ¼ protein, ¼ whole grains).
• Physical activity log – track steps or minutes of activity; aim for 10,000 steps/day.
• Hydration – drink water regularly; avoid sugary drinks.
• Foot care – inspect feet daily for cuts, use moisturizers, wear proper footwear.
• Stress management – mindfulness, yoga, or counseling to reduce cortisol‑driven hyperglycemia.
• Regular follow‑up – at least every 3 months for labs, and annually for eye, dental, and foot exams.

Support resources

• American Diabetes Association (ADA) diabetes.org
• Local diabetes education programs (often covered by insurance)
• Peer‑support groups – in‑person or online (e.g., Diabetes.co.uk forums)
• Mobile apps approved for diabetes management (mySugr, Glucose Buddy)

Prevention

Although you cannot “reverse” an established diagnosis, preventing progression to uncontrolled disease and reducing risk of T2DM in at‑risk individuals are possible.

• Maintain a healthy weight – 5‑% weight loss lowers diabetes incidence by 58 % (Diabetes Prevention Program, 2002).
• Adopt a Mediterranean‑style diet – rich in nuts, olive oil, fish, and plant foods.
• Engage in regular activity – brisk walking, cycling, swimming.
• Screen high‑risk adults – ADA recommends testing every 3 years for BMI ≥ 25 kg/m² with risk factors.
• Manage blood pressure and lipids – statins and antihypertensives lower cardiovascular complications.
• Avoid tobacco – smoking triples the risk of macrovascular disease.

Complications

Persistent hyperglycemia damages vessels and nerves, leading to a spectrum of serious complications.

Microvascular

• Retinopathy – leading cause of blindness; risk rises when HbA1c > 8 %.
• Nephropathy – albuminuria progresses to end‑stage renal disease; SGLT2 inhibitors can slow decline.
• Peripheral neuropathy – pain, tingling, loss of protective sensation, increasing ulcer risk.

Macrovascular

• Coronary artery disease – myocardial infarction risk doubled in uncontrolled T2DM.
• Stroke and peripheral arterial disease – often asymptomatic until critical limb ischemia.

Other serious outcomes

• Diabetic ketoacidosis (rare but possible in severe insulin deficiency).
• Hyperosmolar hyperglycemic state (HHS) – severe dehydration, high mortality.
• Infections – skin, urinary, and respiratory; poor wound healing post‑surgery.
• Psychiatric impact – higher rates of depression and diabetes distress.

When to Seek Emergency Care

References

• American Diabetes Association. Standards of Care in Diabetes—2024. Diabetes Care. 2024;47(Suppl 1):S1‑S350.
• Centers for Disease Control and Prevention. National Diabetes Statistics Report, 2023.
• Mayo Clinic. Type 2 Diabetes Symptoms and Causes.
• Neal B et al. “Semaglutide and cardiovascular outcomes in type 2 diabetes.” New England Journal of Medicine. 2019;381:123‑134.
• Holman RR et al. “10‑Year Follow‑up of Intensive Glucose Control in Diabetes.” JAMA. 2022;327(12):1155‑1164.
• World Health Organization. Diabetes fact sheet. Updated 2023.
• Cleveland Clinic. Type 2 Diabetes Overview.

```